Skip to main content
. 2018 Sep 4;8(5):359–372. doi: 10.1159/000491763

Fig. 3.

Fig. 3

Effect of DPP4i on the size and number of nonalcoholic steatohepatitis-related hepatocellular carcinomas. Representative images of gross hepatic appearance (left) and contrast-enhanced computed tomography scans of the control group (upper row) and the DPP4i group (lower row). DPP4i, dipeptidyl peptidase-4 inhibitor.